Micort-hc label

Micort-hc

Micort-hc Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

History

There is currently no drug history available for this drug.

Other Information

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. Hydrocortisone acetate is a member of this class. Hydrocortisone acetate has a molecular formula of C23H32O6, and its molecular weight of 404.50. The CAS registry number is 50-03-3. The chemical name is Pregn-4-ene-3,20-dione,21-(acetyloxy)-11,17-dihydroxy-, (11P)- and the chemical structural formula is presented below:

Image from Drug Label Content

C23H32O6

MiCort-HC Lipocream 2% is a topical preparation containing hydrocortisone acetate 2% w/w in a water washable cream containing the following inactive ingredients: cetostearyl alcohol, ceteth 20, light mineral oil, white petrolatum, propylparaben, butylparaben, citric acid, sodium citrate, and purified water.

Micort-hc Manufacturers

  • Ferndale Laboratories, Inc.
    Micort-hc | Ferndale Laboratories, Inc.
    No Recall

    Micort-hc | Ferndale Laboratories, Inc.

    Micort-hc | Ferndale Laboratories, Inc.

    Topical corticosteroids are generally applied to the affected areas as a thin film two to four times daily depending on the severity of the condition.

    Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the used of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.